Advanced Technologies Enable Reuse of 18.1 Billion Cubic Meters of Water
15.5.2025 14:00:00 CEST | Business Wire | Press Release
Utilities and businesses around the world have reused 18.1 billion cubic meters of water since 2019, enabled by solutions from global water technology leader Xylem (NYSE: XYL), the Company revealed in its most recent Sustainability Report. That volume is enough to meet the annual water needs of more than 350 million people, based on global use estimates.1
Reuse is just one part of a broader effort to increase global water security – alongside the implementation of advanced treatment and digital technologies. Water managers are using the innovations to protect water sources, remove contaminants, reduce emissions, and make water infrastructure more resilient.
“Our customers are tackling the world’s toughest water challenges,” said Matthew Pine, Xylem President and Chief Executive Officer. “Their results show the impact of scaling proven technology solutions to strengthen water systems. The work they do empowers businesses and communities to become more water-secure.”
In 2019, Xylem launched its 2025 Sustainability Goals, including several targeting the positive impact its technology enables for its customers. Since then, Xylem solutions have enabled customers to:
- Reuse 18.1 billion cubic meters of water, extending the lifecycle and value of freshwater. In the U.S., a global spirits manufacturer identified opportunities to reuse more than 3,785 cubic meters of water annually.
- Reduce non-revenue water in distribution networks by 3.7 billion cubic meters. In Spain, a provincial water utility avoided two major pipeline failures and prevented leaks, saving 25,000 cubic meters of water each year with predictive monitoring and analytics.
- Prevent 10.7 billion cubic meters of polluted water from entering waterways. In the U.S., an advanced treatment service is enabling industrial manufacturers to remove heavy metals from wastewater, reduce hazardous waste, and minimize discharge to local waterways.
- Reduce water-related CO2e emissions by more than 6.4 million metric tons. In Eastern Europe, a food processor cut energy use by 33 percent with an upgrade to smart aeration technology.
Xylem achieved all four of its 2025 Customer Sustainability Goals ahead of schedule. Building on that momentum, the company has set a bold new target: enabling customers to reduce annual water demand by 2 billion cubic meters by 2030.
“We partner with our customers to advance their sustainability ambitions, creating positive impact in the communities we all serve,” said Claudia Toussaint, Chief Sustainability Officer. “This report shows how our commitment to sustainability leadership enhances Xylem’s competitiveness in the marketplace. By embedding sustainability in every aspect of our business and culture, we are empowering our customers and communities to achieve the water security essential to health and economic growth."
Xylem’s impact also extends across its value chain. In 2024, 43% of Xylem’s supplier spending supported partners aligned with WASH4Work, a global initiative focused on expanding access to clean water, sanitation, and hygiene.
About Xylem
Xylem (XYL) is a Fortune 500 leading global water solutions company that empowers customers and communities to build a more water-secure world. Our 23,000 diverse employees delivered revenue of $8.6 billion in 2024, optimizing water and resource management with innovation and expertise. Join us at www.xylem.com and let’s solve water.
| _____________________________ |
| 1 Global per capita domestic water use estimates from the United Nations. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250515880408/en/
Contacts
Media
Houston Spencer
+1 (914) 240-3046
Houston.Spencer@xylem.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom